GC-MS based metabolomic profiling of lung tissue couple with network pharmacology revealed the possible protection mechanism of Pudilan Xiaoyan Oral Liquid in LPS-induced lung injury of mice - 11/02/20
pages | 7 |
Iconographies | 6 |
Vidéos | 0 |
Autres | 0 |
Graphical abstract |
Highlights |
• | GC–MS based metabolomics approach of lung tissue was firstly used to clarify the protective mechanism of PDL. |
• | 11 potential metabolites were identified, which were significantly regulated to recover by PDL treatment. |
• | PDL exerted its protective effect of injured lung by regulating the key protein-metabolite network. |
• | Aspartate and l-cysteine were the key metabolites and their correlated proteins, IL4I1 and ASPA, were speculated as the potential target of PDL. |
Abstract |
Pudilan Xiaoyan Oral Liquid (PDL) originated from "Pudilan" Classic Recipe of traditional Chinese medicine is one kind of anti-inflammatory Chinese patent medicine recorded in Chinese Pharmacopeia. PDL has been used clinically for treating inflammatory diseases of the respiratory tract. However, due to the complex composition of PDL, its potential anti-inflammation and the mechanism remain unknown. To identify the mechanism of the PDL in the treatment of lipopolysaccharide (LPS)-induced lung injury of mice. The mice models of lung injury were established and the changes of biochemical indices in serum and histopathology were detected to explore the effects of PDL. The approach of GC–MS metabolomics was used to find more significant metabolites, and the metabolic pathways were enriched through MetaboAnalyst. Then network analysis was applied to visualize the protein related to the important metabolites, merging into a protein-metabolite network via Cytoscape. The treatment of PDL could attenuate LPS-induced histopathological damage of lung tissues, followed by reducing pro-inflammation mediators including IL-10, TNF-a and NF-ĸB in serum. 11 potential metabolites were identified in lung tissue through metabolomics, which were significantly regulated to recover by PDL treatment. The correlated network was constructed by integrating potential metabolites and pathways. Aspartate and l-cysteine were selected as key metabolites and correlated proteins such as IL4I1 and ASPA were speculated as the potential target to treat LPS-induced lung injury using PDL. These results demonstrated that PDL might prevent the pathological process of lung injury through regulating the disturbed protein-metabolite network.
Le texte complet de cet article est disponible en PDF.Abbreviations : PDL, LPS, TMHM, SBG, CBT, BIB, ALI/ARDS, GC–MS, LC–MS, NMR, TCM, GLN+ALA, CNS, TGF-β1, IL-10, UA, XOR, NF-ĸB, IL-10, TNF-a, PBS, PCA, OPLS-DA
Keywords : Pudilan Xiaoyan Oral Liquid, Metabolomics, Network pharmacology, LPS-induced lung injury, Protective mechanism
Plan
Vol 124
Article 109833- avril 2020 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?